Global Breast Cancer Diagnostics Market
Taille du marché en milliards USD
TCAC :
% 
 Période de prévision |
2024 –2030 |
 Taille du marché (année de référence) |
|
 Taille du marché (année de prévision) |
Dollars américains 8,651.50 |
 TCAC |
% |
| Principaux acteurs du marché |
>Marché mondial du diagnostic du cancer du sein, par type de test (imagerie, biopsie, test génomique , test sanguin et autres), type (carcinome canalaire in situ, carcinome canalaire invasif, cancer du sein inflammatoire et cancer du sein métastatique), utilisateur final (hôpitaux, cliniques, instituts de recherche et universitaires, centres de diagnostic et autres), canal de distribution (appel d'offres direct, vente au détail et autres), tendances et prévisions de l'industrie jusqu'en 2030.
Analyse et perspectives du marché du diagnostic du cancer du sein
Le cancer du sein est la maladie la plus courante dans la population, survenant principalement chez les femmes atteintes de maladies prolifératives. Le cancer du sein se développe principalement dans les tissus mammaires. Les symptômes du cancer du sein comprennent des bosses dans le sein, une différence de taille et de forme des seins, un écoulement des mamelons et des plaques rouges irritées et squameuses sur la peau. L'incidence du cancer du sein chez les femmes augmente à chaque fois que la croissance du marché du cancer du sein augmente avec la croissance des médicaments. Méthodes avancées de diagnostic du cancer du sein avec des techniques développées. Amélioration des technologies développées dans le cancer du sein en augmentant l'efficacité, la précision, l'efficience, la fiabilité et la rapidité des résultats et en améliorant la détection des troubles. Fonctionnalités avancées pour détecter le cancer en moins de temps. Le cancer est détecté à un stade précoce, ce qui aide les patients à récupérer plus rapidement, empêche les cellules cancéreuses de se propager à d'autres parties du corps et les traite avec de nouveaux médicaments sur le marché. L'augmentation du dépistage et de l'imagerie des tumeurs stimulera le marché du cancer du sein. Cela élargit le marché du cancer du sein avec un nombre croissant de patients chaque année, et le taux de guérison du cancer du sein augmente. Soutien gouvernemental en augmentant la disponibilité de nouveaux projets de développement de médicaments et en augmentant l’efficacité et l’efficience du traitement et l’intégration de nouveaux médicaments dans le domaine médical.
Cependant, le coût élevé des traitements de diagnostic du cancer et le manque de professionnels qualifiés sont les facteurs qui freinent la croissance du marché.
Data Bridge Market Research analyse que le marché mondial du diagnostic du cancer du sein devrait atteindre la valeur de 8 651,50 millions USD d'ici 2030, à un TCAC de 9,2 % au cours de la période de prévision. Le type de test représente le segment de type de diagnostic le plus important du marché en raison de l'augmentation du nombre de patientes atteintes du cancer du sein et des avancées technologiques dans le traitement du cancer du sein à l'échelle mondiale. Ce rapport de marché couvre également en profondeur l'analyse des prix, l'analyse des brevets et les avancées technologiques.
|
Rapport métrique |
Détails |
|
Période de prévision |
2023 à 2030 |
|
Année de base |
2022 |
|
Années historiques |
2021 (personnalisable pour 2020-2016) |
|
Unités quantitatives |
Chiffre d'affaires en millions USD, volumes en unités, prix en USD |
|
Segments couverts |
Par type de test (imagerie, biopsie, test génomique, test sanguin et autres), type (carcinome canalaire in situ, carcinome canalaire invasif, cancer du sein inflammatoire et cancer du sein métastatique), utilisateur final (hôpitaux, cliniques, instituts de recherche et universitaires, centres de diagnostic et autres), canal de distribution (appel d'offres direct, vente au détail et autres). |
|
Pays couverts |
États-Unis, Canada, Mexique, Allemagne, France, Royaume-Uni, Italie, Russie, Espagne, Pays-Bas, Suisse, Belgique, Turquie, Irlande et reste de l'Europe, Chine, Japon, Inde, Australie, Corée du Sud, Singapour, Malaisie, Thaïlande, Indonésie, Philippines et reste de l'Asie-Pacifique, Afrique du Sud, Arabie saoudite, Émirats arabes unis, Égypte, Israël et reste du Moyen-Orient et de l'Afrique, Brésil, Argentine et reste de l'Amérique du Sud. |
|
Acteurs du marché couverts |
Les principales entreprises présentes sur le marché sont F-Hoffmann La Roche Ltd., Siemens Healthcare GmbH, General Electric, Koninklijke Philips NV, FUJIFILM Corporation, Abbott, Hologic, Inc., OncoStem, Provista Diagnostics, Thermo Fisher Scientific Inc., Myriad Genetics, Inc., Illumina, Inc., Bio-Rad Laboratories, Inc., BD, NanoString., Cepheid, BIOMÉRIEUX, Exact Sciences Corporation, Biocept, Inc. et Abacus ALS, entre autres. |
Définition du marché mondial du diagnostic du cancer du sein
Le cancer du sein est une maladie caractérisée par une croissance incontrôlée de cellules malignes dans le tissu mammaire, qui survient plus souvent chez les femmes que chez les hommes. Le cancer du sein est la division cellulaire incontrôlée des cellules mammaires, qui sont les cellules les plus courantes dans les glandes et les canaux mammaires. Certains symptômes du cancer du sein comprennent une grosseur ou une masse dans le sein, un écoulement sanguinolent du mamelon et un changement de forme du mamelon ou du sein. Le traitement du cancer du sein dépend du stade du cancer. Son traitement comprend la chimiothérapie, la radiothérapie, l'hormonothérapie et la chirurgie.
Le cancer du sein est un autre type de cancer qui est plus fréquent chez les femmes que chez les hommes. Un certain nombre de symptômes de la maladie comprennent des sécrétions saignantes de l'organe reproducteur, une grosseur ou un blocage dans le sein et des variations de texture ou de forme du sein ou du mamelon. Le traitement du cancer du sein dépend du stade du cancer. En outre, son traitement comprend la radiothérapie, la thérapie, l'hormonothérapie et la chirurgie. La détection précoce du carcinome est essentielle pour le traitement efficace de la maladie. La détection précoce de la maladie conduit également à de meilleurs résultats, notamment de nombreuses options de traitement, une meilleure survie et une meilleure qualité de vie. La pression et la demande croissantes de nouvelles formes ou méthodes de traitement sont dues à la propagation rapide des maladies.
Dynamique du marché mondial du diagnostic du cancer du sein
Cette section traite de la compréhension des moteurs, des avantages, des opportunités, des contraintes et des défis du marché. Tout cela est discuté en détail ci-dessous :
Conducteurs
- Lancement de diagnostics et de thérapies technologiquement avancés pour favoriser la croissance
Le cancer du sein est la maladie la plus courante dans la population, survenant principalement chez les femmes atteintes d'une maladie proliférative. Le cancer du sein se développe dans les tissus mammaires. Les symptômes du cancer du sein comprennent des bosses dans le sein, des différences de taille et de forme du sein, des écoulements au niveau des mamelons et des plaques rouges squameuses qui démangent sur la peau. Cette maladie se propage dans le corps avec des symptômes croissants tels que des douleurs osseuses, des ganglions lymphatiques enflés, des difficultés respiratoires et bien d'autres. L'augmentation de la recherche et du développement avec de nouvelles technologies et de nouveaux traitements développés pour le cancer du sein contribuera considérablement à la croissance du marché.
De plus, les progrès technologiques en matière d’imagerie ouvrent de nouvelles possibilités d’amélioration du dépistage et de la détection précoce. L’une des avancées technologiques est la mammographie 3D, également appelée tomosynthèse mammaire. Cette procédure prend des images sous différents angles autour du sein et les construit en une image de type 3D.
Ces derniers temps, plusieurs avancées technologiques ont changé le destin du diagnostic du cancer. Comme mentionné ci-dessus, plusieurs autres technologies sont actuellement en phase d'essai et sont sur le point de changer le processus de diagnostic du cancer du sein. Ces avancées technologiques dans le domaine agissent comme un moteur majeur du marché mondial du diagnostic du cancer du sein.
- Prévalence croissante du cancer du sein
L’un des principaux facteurs à l’origine de la croissance du marché mondial est la prévalence croissante du cancer du sein dans le monde, ce qui devrait conduire à un grand nombre de patients ayant besoin d’options de traitement précises et efficaces. Le cancer du sein est l’un des cancers les plus courants au monde, et de meilleurs diagnostics devraient augmenter le nombre de patients diagnostiqués à l’avenir.
En outre, la demande croissante de soins préventifs et de traitements précoces a conduit à de nombreux dépistages du cancer, ce qui augmenterait également le nombre de patients ayant un besoin élevé de traitement au cours de la période de prévision.
Ainsi, la prévalence croissante du cancer du sein conduit à un plus grand nombre de diagnostics de cas et devrait donc stimuler la croissance du marché au cours de la période de prévision.
Retenue
- Effets indésirables des traitements contre le cancer du sein
Le dépistage consiste à rechercher un cancer avant que la personne ne présente des symptômes. Cela peut aider à détecter le cancer à un stade précoce. Lorsqu'un tissu anormal ou un cancer est détecté tôt, il peut être plus facile à traiter. Au moment où les symptômes apparaissent, le cancer peut avoir commencé à se propager. Plusieurs tests de dépistage sont utilisés pour détecter les cancers du sein, notamment l'imagerie par résonance magnétique du sein, la mammographie diagnostique, la biopsie, etc. Bien que ces tests soient considérés comme la norme pour le diagnostic du cancer du sein, ils comportent des risques associés, notamment des résultats faussement négatifs, des résultats faussement positifs et des effets secondaires tels qu'un stress psychologique excessif, une exposition excessive aux radiations et un risque grave de rupture de la tumeur et de propagation des cellules cancéreuses.
Opportunité
- Initiatives prises par le gouvernement
Government is focusing on increasing the initiative for breast cancer treatments with advanced techniques to improve the health of patients. Providing he number of insurances, such as benefits, has been increased so that ordinary people can choose treatment and take advantage of available medicines and treatments to improve their quality of life. In developing countries such as China and India, the government has launched several programs and initiatives to raise awareness about the disease. This has greatly increased the demand for breast cancer diagnosis and disease management therapies. Increasing mergers and acquisitions between pharmaceutical companies and government agencies are among the main trends in the global breast cancer market.
Rates of new breast cancer cases have risen 0.6% per year from 2010-2019, and death rates have risen an average of 1.7% per year for the same time frame. As the breast cancer patient rate is increasing, the use of treatments and advanced technologies for the diagnosis of cancer will increase, which is an opportunity for market growth.
Challenge
- Lack of diagnostic infrastructure
Non-communicable diseases such as breast cancer and other types of cancer have now been recognized by the United Nations and WHO as a major public health crisis. Cancer is the biggest part of this problem, and health systems face a major challenge to improve cancer care, control costs and increase system efficiency. Differences in treatment approach and outcomes between high income countries and low and middle income countries are striking. Reasons for this disparity include cost, access to care, workforce and training gaps, and lack of awareness among the lay and medical community.
Moreover, compared to early diagnosis, cancer screening is a separate and more complex public health strategy that requires additional resources, infrastructure and coordination. Rural, developing and low income countries in the different regions does not have enough infrastructure to maintain with the new kits and fro the sample storage as well. These countries need diagnostic infrastructure to ensure the early detection and rapid, accurate diagnosis of the disease.
Post-COVID-19 Impact on Global Breast Cancer Diagnostics Market
The COVID-19 pandemic has caused disruptions in elective health services related to breast screening, pre-cancer care and management of abnormal screening results. This could lead to an increase in the incidence of breast cancer, exacerbating existing health inequalities.
Manufacturers are making various strategic decisions to bounce back post-COVID-19. The players are conducting multiple R&D activities and product launch and strategic partnerships to improve the technology and test results involved in the market.
Recent Developments
- In November 2022, Koninklijke Philips N.V., announced the global launch of a next-generation compact portable ultrasound solution at the Radiological Society of North America (RSNA) annual meeting to bring the diagnostic quality associated with premium cart-based ultrasound systems to more patients. It is portable and versatile with good image quality or performance. It is Compatible with Philips ultrasound systems Affiniti and EPIQ transducer. This has helped company to expand its product portfolio.
- In November 2022, Siemens Healthineers and Atrium Health, a leading not-for-profit healthcare provider known for leading pediatric, cancer and cardiac care programs, have announced a multi-year value partnership1. This strategic agreement focuses on improving access to care in Atrium Health's service area in the southeastern United States, improving health equity and increasing economic mobility. Atrium Health is acquiring more than $140 million in equipment and devices from Siemens Healthineers, including advanced imaging technology, radiation oncology and precision endovascular robotics. This has helped the company to expand their business.
Global Breast Cancer Diagnostics Market Scope
Global breast cancer diagnostics market is segmented into test type, type, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
GLOBAL BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE
- IMAGING
- BIOPSY
- GENOMIC TEST
- BLOOD TEST
- OTHERS
On the basis of test type, the global breast cancer diagnostic market is segmented into imaging, biopsy, genomic test, blood tests and others.
GLOBAL BREAST CANCER DIAGNOSTICS MARKET, BY TYPE
- DUCTAL CARCINOMA IN SITU
- INVASIVE DUCTAL CARCINOMA
- INFLAMMATORY BREAST CANCER
- METASTATIC BREAST CANCER
On the basis of type, the global breast cancer diagnostic market is segmented into ductal in situ carcinoma, invasive ductal carcinoma, inflammatory breast cancer, and metastatic breast cancer.
GLOBAL BREAST CANCER DIAGNOSTICS MARKET, BY END USER
- HOSPITALS
- CLINICS
- RESEARCH & ACADEMIC INSTITUTES
- DIAGNOSTIC CENTERS
- OTHERS
On the basis of end user, the global breast cancer diagnostic market is segmented into hospitals, clinics, research and academic institutes, diagnostic centers and others.
GLOBAL BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL
- DIRECT TENDER
- RETAIL SALES
- OTHERS
On the basis of distribution channel, the global breast cancer diagnostic market is segmented into direct tender, retail sales and others.
Global Breast Cancer Diagnostics Market Regional Analysis/Insights
The global breast cancer diagnostics market is analyzed and market size information is provided test type, type, end user, and distribution channel.
- En 2023, l'Amérique du Nord domine le marché grâce à la présence d'acteurs clés sur le plus grand marché de consommation avec un PIB élevé. Les États-Unis devraient connaître une croissance grâce à leur technologie de pointe en matière de diagnostic du cancer et à leurs inventions dans le domaine du diagnostic du cancer du sein.
L'Amérique du Nord domine le marché en raison de l'augmentation des investissements dans la R&D sur le cancer du sein qui devrait stimuler la croissance du marché. Les États-Unis dominent la région Amérique du Nord en raison de la forte présence des principaux acteurs que sont F-Hoffmann La Roche Ltd., Siemens Healthcare GmbH, General Electric, Koninklijke Philips NV, ABBOTT et d'autres. Le Royaume-Uni domine la région Europe en raison de la production de masse de médicaments de diagnostic du cancer du sein et de la demande croissante des marchés émergents et de l'expansion des industries de traitement du cancer. La Chine domine la région Asie-Pacifique en raison de l'augmentation du cancer du sein principalement parmi la population féminine ainsi que masculine.
La section par pays du rapport fournit également des facteurs d'impact sur les marchés individuels et des changements de réglementation sur le marché national qui ont un impact sur les tendances actuelles et futures du marché. Des points de données tels que les nouvelles ventes, les ventes de remplacement, la démographie des pays, les actes réglementaires et les tarifs d'importation et d'exportation sont quelques-uns des principaux indicateurs utilisés pour prévoir le scénario de marché pour les différents pays. En outre, la présence et la disponibilité des marques mondiales et les défis auxquels elles sont confrontées en raison de la concurrence importante ou rare des marques locales et nationales, ainsi que l'impact des canaux de vente sont pris en compte lors de l'analyse prévisionnelle des données nationales.
Analyse du paysage concurrentiel et des parts de marché mondiales du diagnostic du cancer du sein
Le paysage concurrentiel du marché mondial du diagnostic du cancer du sein fournit des détails par concurrent. Les détails inclus sont la présentation de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements en R&D, les nouvelles initiatives du marché, les sites et installations de production, les forces et les faiblesses de l'entreprise, le lancement de produits, les pipelines d'essais de produits, les approbations de produits, les brevets, la largeur et l'ampleur du produit, la domination des applications, la courbe de survie technologique. Les points de données ci-dessus fournis ne concernent que l'orientation de l'entreprise vers le marché mondial du diagnostic du cancer du sein.
Certains des principaux acteurs opérant sur le marché mondial du diagnostic du cancer du sein sont F-Hoffmann La Roche Ltd., Siemens Healthcare GmbH, General Electric, Koninklijke Philips NV, FUJIFILM Corporation, Abbott, Hologic, Inc., OncoStem, Provista Diagnostics, Thermo Fisher Scientific Inc., Myriad Genetics, Inc., Illumina, Inc., Bio-Rad Laboratories, Inc., BD, NanoString., Cepheid, BIOMÉRIEUX, Exact Sciences Corporation, Biocept, Inc. et Abacus ALS.
SKU-
Accédez en ligne au rapport sur le premier cloud mondial de veille économique
- Tableau de bord d'analyse de données interactif
- Tableau de bord d'analyse d'entreprise pour les opportunités à fort potentiel de croissance
- Accès d'analyste de recherche pour la personnalisation et les requêtes
- Analyse de la concurrence avec tableau de bord interactif
- Dernières actualités, mises à jour et analyse des tendances
- Exploitez la puissance de l'analyse comparative pour un suivi complet de la concurrence
Table des matières
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE GLOBAL BREAST CANCER DIAGNOSTIC MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 MARKET END USER COVERAGE GRID
2.8 TEST TYPE LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER'S 5 FORCES
5 EPIDEMIOLOGY
6 INDUSTRIAL INSIGHTS
7 REGULATORY FRAMEWORK
8 MARKET OVERVIEW
8.1 DRIVERS
8.1.1 LAUNCH OF TECHNOLOGICALLY ADVANCED DIAGNOSIS & THERAPEUTICS TO AID GROWTH
8.1.2 INCREASING PREVALENCE OF BREAST CANCER
8.1.3 GROWING IMPORTANCE OF WOMEN'S HEALTH
8.1.4 RISING AWARENESS TOWARDS THE BREAST CANCER
8.2 RESTRAINTS
8.2.1 ADVERSE EFFECTS OF BREAST CANCER THERAPEUTICS
8.2.2 HIGH COST OF THE IMAGING SYSTEMS
8.3 OPPORTUNITIES
8.3.1 INITIATIVES TAKEN BY THE GOVERNMENT
8.3.2 STRATEGIC INITIATIVES TAKEN BY THE KEY MARKET PLAYERS
8.3.3 GROWTH IN RESEARCH AND DEVELOPMENT OF BREAST CANCER
8.4 CHALLENGES
8.4.1 LACK OF DIAGNOSTIC INFRASTRUCTURE
8.4.2 LACK OF SKILLED PROFESSIONALS FOR PROPER DIAGNOSIS OF BREAST CANCER
9 GLOBAL BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE
9.1 OVERVIEW
9.2 IMAGING
9.2.1 IONIZING BREAST IMAGING TECHNOLOGIES
9.2.1.1 FULL-FIELD DIGITAL MAMMOGRAPHY (FFDM)
9.2.1.2 ANALOG MAMMOGRAPHY
9.2.1.3 3D BREAST TOMOSYNTHESIS
9.2.1.4 POSITRON EMISSION TOMOGRAPHY/ COMPUTED TOMOGRAPHY (PET/CT)
9.2.1.5 MOLECULAR BREAST IMAGING/ BREAST SPECIFIC GAMMA IMAGING (MBI/BSMI)
9.2.1.6 POSITRON EMISSION MAMMOGRAPHY
9.2.1.7 OTHERS
9.2.2 NON-IONIZING IMAGING TECHNOLOGIES
9.2.2.1 OPTICAL IMAGING
9.2.2.2 BREAST ULTRASOUND
9.2.2.3 BREAST MRI (MAGNETIC RESONANCE IMAGING)
9.2.2.4 AUTOMATED WHOLE BREAST ULTRASOUND (AWBU)
9.2.2.5 BREAST THERMOGRAPHY
9.2.3 BIOPSY
9.2.3.1 SURGICAL BIOPSY
9.2.3.2 FINE NEEDLE ASPIRATION BIOPSY
9.2.3.3 CORE NEEDLE BIOPSY
9.2.3.4 IMAGE-GUIDED BIOPSY
9.2.3.5 SENTINEL LYMPH NODE BIOPSY
9.2.4 GENOMIC TEST
9.2.4.1 MOLECULAR TESTING
9.2.4.1.1 PD-L1
9.2.4.1.2 MICROSATELLITE INSTABILITY-HIGH (MSI-H) OR DNA MISMATCH REPAIR DEFICIENCY (DMMR)
9.2.4.1.3 NTRK GENE FUSIONS
9.2.4.1.4 PI3KCA GENE MUTATION
9.2.4.2 MAMMAPRINT
9.2.4.3 ONCOTYPE DX
9.2.4.4 OTHERS
9.3 BLOOD TEST
9.4 OTHERS
10 GLOBAL BREAST CANCER DIAGNOSTICS MARKET, BY TYPE
10.1 OVERVIEW
10.2 INVASIVE DUCTAL CARCINOMA
10.3 DUCTAL CARCINOMA IN SITU
10.4 INFLAMMATORY BREAST CANCER
10.5 METASTATIC BREAST CANCER
11 GLOBAL BREAST CANCER DIAGNOSTICS MARKET, BY END USER
11.1 OVERVIEW
11.2 HOSPITALS
11.3 DIAGNOSTICS CENTERS
11.4 CLINICS
11.5 RESEARCH & ACADEMIC INSTITUTES
11.6 OTHERS
12 GLOBAL BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL
12.1 OVERVIEW
12.2 DIRECT TENDER
12.3 RETAIL SALES
12.4 OTHERS
13 GLOBAL BREAST CANCER DIAGNOSTICS MARKET, BY REGION
13.1 OVERVIEW
13.2 NORTH AMERICA
13.2.1 U.S.
13.2.2 CANADA
13.2.3 MEXICO
13.3 EUROPE
13.3.1 GERMANY
13.3.2 FRANCE
13.3.3 RUSSIA
13.3.4 ITALY
13.3.5 U.K.
13.3.6 SPAIN
13.3.7 TURKEY
13.3.8 NETHERLANDS
13.3.9 BELGIUM
13.3.10 SWITZERLAND
13.3.11 IRELAND
13.3.12 REST OF EUROPE
13.4 ASIA-PACIFIC
13.4.1 CHINA
13.4.2 INDIA
13.4.3 JAPAN
13.4.4 INDONESIA
13.4.5 PHILIPPINES
13.4.6 THAILAND
13.4.7 AUSTRALIA
13.4.8 MALAYSIA
13.4.9 SOUTH KOREA
13.4.10 SINGAPORE
13.4.11 REST OF ASIA-PACIFIC
13.5 SOUTH AMERICA
13.5.1 BRAZIL
13.5.2 ARGENTINA
13.5.3 REST OF SOUTH AMERICA
13.6 MIDDLE EAST AND AFRICA
13.6.1 EGYPT
13.6.2 SOUTH AFRICA
13.6.3 ISRAEL
13.6.4 SAUDI ARABIA
13.6.5 UAE
13.6.6 REST OF MIDDLE EAST AND AFRICA
14 GLOBAL BREAST CANCER DIAGNOSTICS MARKET, COMPANY LANDSCAPE
14.1 COMPANY SHARE ANALYSIS: GLOBAL
14.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
14.3 COMPANY SHARE ANALYSIS: EUROPE
14.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
15 SWOT ANALYSIS
16 COMPANY PROFILE
16.1 HOLOGIC, INC.
16.1.1 COMPANY SNAPSHOT
16.1.2 REVENUE ANALYSIS
16.1.3 COMPANY SHARE ANALYSIS
16.1.4 PRODUCT PORTFOLIO
16.1.5 RECENT DEVELOPMENTS
16.2 SIEMENS HEALTHCARE GMBH
16.2.1 COMPANY SNAPSHOT
16.2.2 REVENUE ANALYSIS
16.2.3 COMPANY SHARE ANALYSIS
16.2.4 PRODUCT PORTFOLIO
16.2.5 RECENT DEVELOPMENTS
16.3 F. HOFFMANN- LA ROCHE LTD
16.3.1 COMPANY SNAPSHOT
16.3.2 REVENUE ANALYSIS
16.3.3 COMPANY SHARE ANALYSIS
16.3.4 PRODUCT PORTFOLIO
16.3.5 RECENT DEVELOPMENTS
16.4 KONINKLIJKE PHILIPS N.V.
16.4.1 COMPANY SNAPSHOT
16.4.2 REVENUE ANALYSIS
16.4.3 COMPANY SHARE ANALYSIS
16.4.4 PRODUCT PORTFOLIO
16.4.5 RECENT DEVELOPMENTS
16.5 ABBOTT
16.5.1 COMPANY SNAPSHOT
16.5.2 REVENUE ANALYSIS
16.5.3 COMPANY SHARE ANALYSIS
16.5.4 PRODUCT PORTFOLIO
16.5.5 RECENT DEVELOPMENTS
16.6 ABACUS ALS
16.6.1 COMPANY SNAPSHOT
16.6.2 PRODUCT PORTFOLIO
16.6.3 RECENT DEVELOPMENTS
16.7 BD
16.7.1 COMPANY SNAPSHOT
16.7.2 REVENUE ANALYSIS
16.7.3 COMPANY SHARE ANALYSIS
16.7.4 PRODUCT PORTFOLIO
16.7.5 RECENT DEVELOPMENTS
16.8 BIOCEPT, INC.
16.8.1 COMPANY SNAPSHOT
16.8.2 REVENUE ANALYSIS
16.8.3 PRODUCT PORTFOLIO
16.8.4 RECENT DEVELOPMENTS
16.9 BIOMÉRIEUX
16.9.1 COMPANY SNAPSHOT
16.9.2 REVENUE ANALYSIS
16.9.3 PRODUCT PORTFOLIO
16.9.4 RECENT DEVELOPMENTS
16.1 BIO-RAD LABORATORIES, INC.
16.10.1 COMPANY SNAPSHOT
16.10.2 REVENUE ANALYSIS
16.10.3 PRODUCT PORTFOLIO
16.10.4 RECENT DEVELOPMENT
16.11 CEPHEID
16.11.1 COMPANY SNAPSHOT
16.11.2 REVENUE ANALYSIS
16.11.3 PRODUCT PORTFOLIO
16.11.4 RECENT DEVELOPMENT
16.12 EXACT SCIENCES CORPORATION
16.12.1 COMPANY SNAPSHOT
16.12.2 REVENUE ANALYSIS
16.12.3 COMPANY SHARE ANALYSIS
16.12.4 PRODUCT PORTFOLIO
16.12.5 RECENT DEVELOPMENTS
16.13 FUJIFILM CORPORATION
16.13.1 COMPANY SNAPSHOT
16.13.2 REVENUE ANALYSIS
16.13.3 PRODUCT PORTFOLIO
16.13.4 RECENT DEVELOPMENT
16.14 GENERAL ELECTRIC
16.14.1 COMPANY SNAPSHOT
16.14.2 REVENUE ANALYSIS
16.14.3 PRODUCT PORTFOLIO
16.14.4 RECENT DEVELOPMENTS
16.15 ILLUMINA, INC.
16.15.1 COMPANY SNAPSHOT
16.15.2 REVENUE ANALYSIS
16.15.3 PRODUCT PORTFOLIO
16.15.4 RECENT DEVELOPMENTS
16.16 MYRIAD GENETICS, INC.
16.16.1 COMPANY SNAPSHOT
16.16.2 REVENUE ANALYSIS
16.16.3 PRODUCT PORTFOLIO
16.16.4 RECENT DEVELOPMENT
16.17 NANOSTRING.
16.17.1 COMPANY SNAPSHOT
16.17.2 REVENUE ANALYSIS
16.17.3 PRODUCT PORTFOLIO
16.17.4 RECENT DEVELOPMENT
16.17.5 RECENT DEVELOPMENT
16.18 ONCOSTEM.
16.18.1 COMPANY SNAPSHOT
16.18.2 PRODUCT PORTFOLIO
16.18.3 RECENT DEVELOPMENT
16.19 PROVISTA DIAGNOSTICS.
16.19.1 COMPANY SNAPSHOT
16.19.2 PRODUCT PORTFOLIO
16.19.3 RECENT DEVELOPMENT
16.2 THERMO FISHER SCIENTIFIC INC.
16.20.1 COMPANY SNAPSHOT
16.20.2 REVENUE ANALYSIS
16.20.3 PRODUCT PORTFOLIO
16.20.4 RECENT DEVELOPMENT
17 QUESTIONNAIRE
18 RELATED REPORTS
Liste des tableaux
TABLE 1 INCIDENCE RATE OF BREAST CANCER (2020)
TABLE 2 MORTALITY RATE OF BREAST CANCER (2020)
TABLE 3 INCIDENCE OF DUCTAL CARCINOMA IN SITU (DCIS) BREAST CANCER
TABLE 4 GLOBAL BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 5 GLOBAL IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 6 GLOBAL IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 7 GLOBAL IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 8 GLOBAL IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 9 GLOBAL NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 10 GLOBAL NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 11 GLOBAL BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 12 GLOBAL BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 13 GLOBAL BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 14 GLOBAL GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 15 GLOBAL GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 16 GLOBAL GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 17 GLOBAL MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 18 GLOBAL MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 19 GLOBAL BLOOD TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 20 GLOBAL OTHERS IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 21 GLOBAL BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 22 GLOBAL INVASIVE DUCTAL CARCINOMA IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 23 GLOBAL DUCTAL CARCINOMA IN SITU IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 24 GLOBAL INFLAMMATORY BREAST CANCER IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 25 GLOBAL METASTATIC BREAST CANCER IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 26 GLOBAL BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 27 GLOBAL HOSPITALS IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 28 GLOBAL DIAGNOSTIC CENTERS IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 29 GLOBAL CLINICS IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 30 GLOBAL RESEARCH AND ACADEMIC INSTITUTES IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 31 GLOBAL OTHERS IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 32 GLOBAL BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 33 GLOBAL DIRECT TENDER IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 34 GLOBAL RETAIL SALES IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 35 GLOBAL OTHERS IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 36 GLOBAL BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 37 NORTH AMERICA BREAST CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 38 NORTH AMERICA BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 39 NORTH AMERICA IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 40 NORTH AMERICA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 41 NORTH AMERICA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 42 NORTH AMERICA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 43 NORTH AMERICA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 44 NORTH AMERICA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 45 NORTH AMERICA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 46 NORTH AMERICA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 47 NORTH AMERICA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 48 NORTH AMERICA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 49 NORTH AMERICA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 50 NORTH AMERICA BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 51 NORTH AMERICA BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 52 NORTH AMERICA BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 53 U.S. BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 54 U.S. IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 55 U.S. IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 56 U.S. IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 57 U.S. IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 58 U.S. NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 59 U.S. NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 60 U.S. NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 61 U.S. BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 62 U.S. BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 63 U.S. BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 64 U.S. GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 65 U.S. GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 66 U.S. GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 67 U.S. MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 68 U.S. MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 69 U.S. MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 70 U.S. BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 71 U.S. BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 72 U.S. BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 73 CANADA BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 74 CANADA IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 75 CANADA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 76 CANADA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 77 CANADA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 78 CANADA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 79 CANADA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 80 CANADA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 81 CANADA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 82 CANADA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 83 CANADA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 84 CANADA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 85 CANADA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 86 CANADA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 87 CANADA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 88 CANADA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 89 CANADA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 90 CANADA BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 91 CANADA BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 92 CANADA BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 93 MEXICO BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 94 MEXICO IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 95 MEXICO IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 96 MEXICO IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 97 MEXICO IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 98 MEXICO NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 99 MEXICO NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 100 MEXICO NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 101 MEXICO BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 102 MEXICO BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 103 MEXICO BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 104 MEXICO GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 105 MEXICO GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 106 MEXICO GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 107 MEXICO MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 108 MEXICO MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 109 MEXICO MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 110 MEXICO BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 111 MEXICO BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 112 MEXICO BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 113 EUROPE BREAST CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 114 EUROPE BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 115 EUROPE IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 116 EUROPE IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 117 EUROPE IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 118 EUROPE NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 119 EUROPE NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 120 EUROPE BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 121 EUROPE BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 122 EUROPE GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 123 EUROPE GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 124 EUROPE MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 125 EUROPE MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 126 EUROPE BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 127 EUROPE BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 128 EUROPE BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 129 GERMANY BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 130 GERMANY IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 131 GERMANY IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 132 GERMANY IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 133 GERMANY IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 134 GERMANY NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 135 GERMANY NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 136 GERMANY NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 137 GERMANY BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 138 GERMANY BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 139 GERMANY BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 140 GERMANY GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 141 GERMANY GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 142 GERMANY GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 143 GERMANY MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 144 GERMANY MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 145 GERMANY MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 146 GERMANY BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 147 GERMANY BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 148 GERMANY BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 149 FRANCE BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 150 FRANCE IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 151 FRANCE IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 152 FRANCE IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 153 FRANCE IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 154 FRANCE NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 155 FRANCE NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 156 FRANCE NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 157 FRANCE BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 158 FRANCE BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 159 FRANCE BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 160 FRANCE GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 161 FRANCE GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 162 FRANCE GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 163 FRANCE MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 164 FRANCE MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 165 FRANCE MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 166 FRANCE BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 167 FRANCE BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 168 FRANCE BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 169 RUSSIA BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 170 RUSSIA IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 171 RUSSIA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 172 RUSSIA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 173 RUSSIA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 174 RUSSIA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 175 RUSSIA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 176 RUSSIA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 177 RUSSIA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 178 RUSSIA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 179 RUSSIA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 180 RUSSIA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 181 RUSSIA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 182 RUSSIA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 183 RUSSIA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 184 RUSSIA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 185 RUSSIA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 186 RUSSIA BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 187 RUSSIA BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 188 RUSSIA BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 189 ITALY BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 190 ITALY IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 191 ITALY IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 192 ITALY IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 193 ITALY IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 194 ITALY NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 195 ITALY NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 196 ITALY NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 197 ITALY BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 198 ITALY BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 199 ITALY BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 200 ITALY GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 201 ITALY GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 202 ITALY GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 203 ITALY MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 204 ITALY MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 205 ITALY MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 206 ITALY BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 207 ITALY BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 208 ITALY BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 209 U.K. BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 210 U.K. IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 211 U.K. IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 212 U.K. IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 213 U.K. IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 214 U.K. NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 215 U.K. NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 216 U.K. NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 217 U.K. BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 218 U.K. BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 219 U.K. BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 220 U.K. GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 221 U.K. GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 222 U.K. GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 223 U.K. MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 224 U.K. MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 225 U.K. MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 226 U.K. BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 227 U.K. BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 228 U.K. BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 229 SPAIN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 230 SPAIN IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 231 SPAIN IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 232 SPAIN IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 233 SPAIN IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 234 SPAIN NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 235 SPAIN NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 236 SPAIN NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 237 SPAIN BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 238 SPAIN BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 239 SPAIN BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 240 SPAIN GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 241 SPAIN GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 242 SPAIN GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 243 SPAIN MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 244 SPAIN MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 245 SPAIN MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 246 SPAIN BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 247 SPAIN BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 248 SPAIN BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 249 TURKEY BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 250 TURKEY IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 251 TURKEY IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 252 TURKEY IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 253 TURKEY IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 254 TURKEY NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 255 TURKEY NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 256 TURKEY NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 257 TURKEY BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 258 TURKEY BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 259 TURKEY BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 260 TURKEY GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 261 TURKEY GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 262 TURKEY GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 263 TURKEY MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 264 TURKEY MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 265 TURKEY MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 266 TURKEY BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 267 TURKEY BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 268 TURKEY BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 269 NETHERLANDS BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 270 NETHERLANDS IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 271 NETHERLANDS IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 272 NETHERLANDS IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 273 NETHERLANDS IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 274 NETHERLANDS NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 275 NETHERLANDS NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 276 NETHERLANDS NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 277 NETHERLANDS BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 278 NETHERLANDS BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 279 NETHERLANDS BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 280 NETHERLANDS GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 281 NETHERLANDS GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 282 NETHERLANDS GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 283 NETHERLANDS MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 284 NETHERLANDS MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 285 NETHERLANDS MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 286 NETHERLANDS BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 287 NETHERLANDS BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 288 NETHERLANDS BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 289 BELGIUM BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 290 BELGIUM IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 291 BELGIUM IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 292 BELGIUM IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 293 BELGIUM IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 294 BELGIUM NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 295 BELGIUM NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 296 BELGIUM NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 297 BELGIUM BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 298 BELGIUM BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 299 BELGIUM BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 300 BELGIUM GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 301 BELGIUM GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 302 BELGIUM GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 303 BELGIUM MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 304 BELGIUM MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 305 BELGIUM MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 306 BELGIUM BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 307 BELGIUM BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 308 BELGIUM BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 309 SWITZERLAND BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 310 SWITZERLAND IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 311 SWITZERLAND IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 312 SWITZERLAND IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 313 SWITZERLAND IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 314 SWITZERLAND NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 315 SWITZERLAND NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 316 SWITZERLAND NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 317 SWITZERLAND BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 318 SWITZERLAND BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 319 SWITZERLAND BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 320 SWITZERLAND GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 321 SWITZERLAND GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 322 SWITZERLAND GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 323 SWITZERLAND MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 324 SWITZERLAND MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 325 SWITZERLAND MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 326 SWITZERLAND BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 327 SWITZERLAND BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 328 SWITZERLAND BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 329 IRELAND BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 330 IRELAND IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 331 IRELAND IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 332 IRELAND IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 333 IRELAND IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 334 IRELAND NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 335 IRELAND NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 336 IRELAND NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 337 IRELAND BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 338 IRELAND BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 339 IRELAND BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 340 IRELAND GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 341 IRELAND GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 342 IRELAND GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 343 IRELAND MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 344 IRELAND MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 345 IRELAND MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 346 IRELAND BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 347 IRELAND BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 348 IRELAND BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 349 REST OF EUROPE BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 350 ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 351 ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 352 ASIA-PACIFIC IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 353 ASIA-PACIFIC IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 354 ASIA-PACIFIC IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 355 ASIA-PACIFIC NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 356 ASIA-PACIFIC NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 357 ASIA-PACIFIC BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 358 ASIA-PACIFIC BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 359 ASIA-PACIFIC GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 360 ASIA-PACIFIC GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 361 ASIA-PACIFIC MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 362 ASIA-PACIFIC MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 363 ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 364 ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 365 ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 366 CHINA BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 367 CHINA IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 368 CHINA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 369 CHINA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 370 CHINA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 371 CHINA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 372 CHINA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 373 CHINA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 374 CHINA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 375 CHINA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 376 CHINA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 377 CHINA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 378 CHINA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 379 CHINA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 380 CHINA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 381 CHINA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 382 CHINA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 383 CHINA BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 384 CHINA BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 385 CHINA BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 386 INDIA BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 387 INDIA IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 388 INDIA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 389 INDIA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 390 INDIA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 391 INDIA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 392 INDIA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 393 INDIA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 394 INDIA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 395 INDIA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 396 INDIA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 397 INDIA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 398 INDIA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 399 INDIA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 400 INDIA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 401 INDIA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 402 INDIA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 403 INDIA BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 404 INDIA BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 405 INDIA BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 406 JAPAN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 407 JAPAN IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 408 JAPAN IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 409 JAPAN IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 410 JAPAN IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 411 JAPAN NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 412 JAPAN NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 413 JAPAN NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 414 JAPAN BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 415 JAPAN BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 416 JAPAN BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 417 JAPAN GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 418 JAPAN GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 419 JAPAN GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 420 JAPAN MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 421 JAPAN MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 422 JAPAN MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 423 JAPAN BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 424 JAPAN BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 425 JAPAN BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 426 INDONESIA BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 427 INDONESIA IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 428 INDONESIA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 429 INDONESIA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 430 INDONESIA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 431 INDONESIA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 432 INDONESIA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 433 INDONESIA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 434 INDONESIA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 435 INDONESIA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 436 INDONESIA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 437 INDONESIA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 438 INDONESIA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 439 INDONESIA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 440 INDONESIA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 441 INDONESIA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 442 INDONESIA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 443 INDONESIA BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 444 INDONESIA BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 445 INDONESIA BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 446 PHILIPPINES BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 447 PHILIPPINES IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 448 PHILIPPINES IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 449 PHILIPPINES IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 450 PHILIPPINES IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 451 PHILIPPINES NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 452 PHILIPPINES NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 453 PHILIPPINES NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 454 PHILIPPINES BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 455 PHILIPPINES BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 456 PHILIPPINES BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 457 PHILIPPINES GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 458 PHILIPPINES GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 459 PHILIPPINES GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 460 PHILIPPINES MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 461 PHILIPPINES MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 462 PHILIPPINES MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 463 PHILIPPINES BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 464 PHILIPPINES BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 465 PHILIPPINES BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 466 THAILAND BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 467 THAILAND IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 468 THAILAND IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 469 THAILAND IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 470 THAILAND IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 471 THAILAND NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 472 THAILAND NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 473 THAILAND NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 474 THAILAND BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 475 THAILAND BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 476 THAILAND BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 477 THAILAND GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 478 THAILAND GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 479 THAILAND GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 480 THAILAND MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 481 THAILAND MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 482 THAILAND MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 483 THAILAND BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 484 THAILAND BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 485 THAILAND BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 486 AUSTRALIA BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 487 AUSTRALIA IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 488 AUSTRALIA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 489 AUSTRALIA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 490 AUSTRALIA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 491 AUSTRALIA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 492 AUSTRALIA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 493 AUSTRALIA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 494 AUSTRALIA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 495 AUSTRALIA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 496 AUSTRALIA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 497 AUSTRALIA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 498 AUSTRALIA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 499 AUSTRALIA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 500 AUSTRALIA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 501 AUSTRALIA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 502 AUSTRALIA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 503 AUSTRALIA BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 504 AUSTRALIA BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 505 AUSTRALIA BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 506 MALAYSIA BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 507 MALAYSIA IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 508 MALAYSIA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 509 MALAYSIA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 510 MALAYSIA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 511 MALAYSIA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 512 MALAYSIA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 513 MALAYSIA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 514 MALAYSIA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 515 MALAYSIA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 516 MALAYSIA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 517 MALAYSIA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 518 MALAYSIA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 519 MALAYSIA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 520 MALAYSIA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 521 MALAYSIA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 522 MALAYSIA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 523 MALAYSIA BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 524 MALAYSIA BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 525 MALAYSIA BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 526 SOUTH KOREA BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 527 SOUTH KOREA IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 528 SOUTH KOREA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 529 SOUTH KOREA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 530 SOUTH KOREA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 531 SOUTH KOREA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 532 SOUTH KOREA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 533 SOUTH KOREA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 534 SOUTH KOREA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 535 SOUTH KOREA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 536 SOUTH KOREA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 537 SOUTH KOREA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 538 SOUTH KOREA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 539 SOUTH KOREA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 540 SOUTH KOREA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 541 SOUTH KOREA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 542 SOUTH KOREA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 543 SOUTH KOREA BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 544 SOUTH KOREA BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 545 SOUTH KOREA BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 546 SINGAPORE BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 547 SINGAPORE IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 548 SINGAPORE IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 549 SINGAPORE IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 550 SINGAPORE IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 551 SINGAPORE NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 552 SINGAPORE NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 553 SINGAPORE NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 554 SINGAPORE BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 555 SINGAPORE BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 556 SINGAPORE BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 557 SINGAPORE GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 558 SINGAPORE GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 559 SINGAPORE GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 560 SINGAPORE MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 561 SINGAPORE MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 562 SINGAPORE MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 563 SINGAPORE BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 564 SINGAPORE BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 565 SINGAPORE BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 566 REST OF ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 567 SOUTH AMERICA BREAST CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 568 SOUTH AMERICA BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 569 SOUTH AMERICA IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 570 SOUTH AMERICA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 571 SOUTH AMERICA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 572 SOUTH AMERICA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 573 SOUTH AMERICA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 574 SOUTH AMERICA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 575 SOUTH AMERICA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 576 SOUTH AMERICA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 577 SOUTH AMERICA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 578 SOUTH AMERICA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 579 SOUTH AMERICA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 580 SOUTH AMERICA BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 581 SOUTH AMERICA BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 582 SOUTH AMERICA BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 583 BRAZIL BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 584 BRAZIL IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 585 BRAZIL IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 586 BRAZIL IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 587 BRAZIL IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 588 BRAZIL NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 589 BRAZIL NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 590 BRAZIL NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 591 BRAZIL BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 592 BRAZIL BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 593 BRAZIL BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 594 BRAZIL GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 595 BRAZIL GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 596 BRAZIL GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 597 BRAZIL MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 598 BRAZIL MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 599 BRAZIL MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 600 BRAZIL BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 601 BRAZIL BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 602 BRAZIL BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 603 ARGENTINA BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 604 ARGENTINA IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 605 ARGENTINA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 606 ARGENTINA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 607 ARGENTINA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 608 ARGENTINA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 609 ARGENTINA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 610 ARGENTINA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 611 ARGENTINA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 612 ARGENTINA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 613 ARGENTINA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 614 ARGENTINA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 615 ARGENTINA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 616 ARGENTINA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 617 ARGENTINA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 618 ARGENTINA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 619 ARGENTINA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 620 ARGENTINA BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 621 ARGENTINA BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 622 ARGENTINA BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 623 REST OF SOUTH AMERICA BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 624 MIDDLE EAST AND AFRICA BREAST CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 625 MIDDLE EAST AND AFRICA BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 626 MIDDLE EAST AND AFRICA IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 627 MIDDLE EAST AND AFRICA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 628 MIDDLE EAST AND AFRICA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 629 MIDDLE EAST AND AFRICA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 630 MIDDLE EAST AND AFRICA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 631 MIDDLE EAST AND AFRICA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 632 MIDDLE EAST AND AFRICA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 633 MIDDLE EAST AND AFRICA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 634 MIDDLE EAST AND AFRICA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 635 MIDDLE EAST AND AFRICA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 636 MIDDLE EAST AND AFRICA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 637 MIDDLE EAST AND AFRICA BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 638 MIDDLE EAST AND AFRICA BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 639 MIDDLE EAST AND AFRICA BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 640 EGYPT BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 641 EGYPT IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 642 EGYPT IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 643 EGYPT IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 644 EGYPT IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 645 EGYPT NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 646 EGYPT NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 647 EGYPT NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 648 EGYPT BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 649 EGYPT BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 650 EGYPT BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 651 EGYPT GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 652 EGYPT GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 653 EGYPT GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 654 EGYPT MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 655 EGYPT MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 656 EGYPT MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 657 EGYPT BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 658 EGYPT BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 659 EGYPT BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 660 SOUTH AFRICA BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 661 SOUTH AFRICA IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 662 SOUTH AFRICA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 663 SOUTH AFRICA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 664 SOUTH AFRICA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 665 SOUTH AFRICA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 666 SOUTH AFRICA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 667 SOUTH AFRICA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 668 SOUTH AFRICA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 669 SOUTH AFRICA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 670 SOUTH AFRICA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 671 SOUTH AFRICA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 672 SOUTH AFRICA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 673 SOUTH AFRICA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 674 SOUTH AFRICA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 675 SOUTH AFRICA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 676 SOUTH AFRICA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 677 SOUTH AFRICA BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 678 SOUTH AFRICA BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 679 SOUTH AFRICA BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 680 ISRAEL BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 681 ISRAEL IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 682 ISRAEL IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 683 ISRAEL IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 684 ISRAEL IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 685 ISRAEL NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 686 ISRAEL NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 687 ISRAEL NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 688 ISRAEL BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 689 ISRAEL BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 690 ISRAEL BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 691 ISRAEL GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 692 ISRAEL GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 693 ISRAEL GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 694 ISRAEL MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 695 ISRAEL MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 696 ISRAEL MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 697 ISRAEL BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 698 ISRAEL BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 699 ISRAEL BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 700 SAUDI ARABIA BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 701 SAUDI ARABIA IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 702 SAUDI ARABIA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 703 SAUDI ARABIA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 704 SAUDI ARABIA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 705 SAUDI ARABIA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 706 SAUDI ARABIA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 707 SAUDI ARABIA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 708 SAUDI ARABIA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 709 SAUDI ARABIA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 710 SAUDI ARABIA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 711 SAUDI ARABIA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 712 SAUDI ARABIA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 713 SAUDI ARABIA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 714 SAUDI ARABIA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 715 SAUDI ARABIA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 716 SAUDI ARABIA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 717 SAUDI ARABIA BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 718 SAUDI ARABIA BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 719 SAUDI ARABIA BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 720 UAE BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 721 UAE IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 722 UAE IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 723 UAE IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 724 UAE IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 725 UAE NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 726 UAE NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 727 UAE NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 728 UAE BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 729 UAE BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 730 UAE BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 731 UAE GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 732 UAE GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 733 UAE GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 734 UAE MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 735 UAE MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 736 UAE MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 737 UAE BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 738 UAE BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 739 UAE BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 740 REST OF MIDDLE EAST AND AFRICA BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
Liste des figures
FIGURE 1 GLOBAL BREAST CANCER DIAGNOSTIC MARKET: SEGMENTATION
FIGURE 2 GLOBAL BREAST CANCER DIAGNOSTIC MARKET: DATA TRIANGULATION
FIGURE 3 GLOBAL BREAST CANCER DIAGNOSTIC MARKET: DROC ANALYSIS
FIGURE 4 GLOBAL BREAST CANCER DIAGNOSTIC MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS
FIGURE 5 GLOBAL BREAST CANCER DIAGNOSTIC MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 GLOBAL BREAST CANCER DIAGNOSTIC MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 GLOBAL BREAST CANCER DIAGNOSTIC MARKET: MARKET END USER COVERAGE GRID
FIGURE 8 GLOBAL BREAST CANCER DIAGNOSTIC MARKET: DBMR MARKET POSITION GRID
FIGURE 9 GLOBAL BREAST CANCER DIAGNOSTIC MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 GLOBAL BREAST CANCER DIAGNOSTIC MARKET: SEGMENTATION
FIGURE 11 GROWING AWARENESS OF BREAST CANCER AND INCREASING HEALTHCARE EXPENDITURE IS EXPECTED TO DRIVE THE GROWTH OF THE GLOBAL BREAST CANCER DIAGNOSTIC MARKET FROM 2023 TO 2030
FIGURE 12 THE IMAGING SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL BREAST CANCER DIAGNOSTIC MARKET IN 2023 & 2030
FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE GLOBAL BREAST CANCER DIAGNOSTIC MARKET, AND ASIA PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2023 TO 2030
FIGURE 14 ASIA-PACIFIC IS THE FASTEST-GROWING MARKET FOR GLOBAL BREAST CANCER DIAGNOSTICS MARKET MANUFACTURERS IN THE FORECAST PERIOD OF 2023 TO 2030
FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE GLOBAL BREAST CANCER DIAGNOSTICS MARKET
FIGURE 16 GLOBAL BREAST CANCER DIAGNOSTICS MARKET : BY TEST TYPE, 2022
FIGURE 17 GLOBAL BREAST CANCER DIAGNOSTICS MARKET : BY TEST TYPE, 2023-2030 (USD MILLION)
FIGURE 18 GLOBAL BREAST CANCER DIAGNOSTICS MARKET : BY TEST TYPE, CAGR (2023-2030)
FIGURE 19 GLOBAL BREAST CANCER DIAGNOSTICS MARKET : BY TEST TYPE, LIFELINE CURVE
FIGURE 20 GLOBAL BREAST CANCER DIAGNOSTICS MARKET : BY TYPE, 2022
FIGURE 21 GLOBAL BREAST CANCER DIAGNOSTICS MARKET : BY TYPE, 2023-2030 (USD MILLION)
FIGURE 22 GLOBAL BREAST CANCER DIAGNOSTICS MARKET : BY TYPE, CAGR (2023-2030)
FIGURE 23 GLOBAL BREAST CANCER DIAGNOSTICS MARKET : BY TYPE, LIFELINE CURVE
FIGURE 24 GLOBAL BREAST CANCER DIAGNOSTICS MARKET : BY END USER, 2022
FIGURE 25 GLOBAL BREAST CANCER DIAGNOSTICS MARKET : BY END USER, 2023-2030 (USD MILLION)
FIGURE 26 GLOBAL BREAST CANCER DIAGNOSTICS MARKET : BY END USER, CAGR (2023-2030)
FIGURE 27 GLOBAL BREAST CANCER DIAGNOSTICS MARKET : BY END USER, LIFELINE CURVE
FIGURE 28 GLOBAL BREAST CANCER DIAGNOSTICS MARKET : BY DISTRIBUTION CHANNEL, 2022
FIGURE 29 GLOBAL BREAST CANCER DIAGNOSTICS MARKET : BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)
FIGURE 30 GLOBAL BREAST CANCER DIAGNOSTICS MARKET : BY DISTRIBUTION CHANNEL, CAGR (2023-2030)
FIGURE 31 GLOBAL BREAST CANCER DIAGNOSTICS MARKET : BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 32 GLOBAL BREAST CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022)
FIGURE 33 GLOBAL BREAST CANCER DIAGNOSTICS MARKET: BY REGION (2022)
FIGURE 34 GLOBAL BREAST CANCER DIAGNOSTICS MARKET: BY REGION (2023 & 2030)
FIGURE 35 GLOBAL BREAST CANCER DIAGNOSTICS MARKET: BY REGION (2022 & 2030)
FIGURE 36 GLOBAL BREAST CANCER DIAGNOSTICS MARKET: BY TEST TYPE (2023-2030)
FIGURE 37 NORTH AMERICA BREAST CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022)
FIGURE 38 NORTH AMERICA BREAST CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022)
FIGURE 39 NORTH AMERICA BREAST CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030)
FIGURE 40 NORTH AMERICA BREAST CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030)
FIGURE 41 NORTH AMERICA BREAST CANCER DIAGNOSTICS MARKET: TEST TYPE (2023-2030)
FIGURE 42 EUROPE BREAST CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022)
FIGURE 43 EUROPE BREAST CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022)
FIGURE 44 EUROPE BREAST CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030)
FIGURE 45 EUROPE BREAST CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030)
FIGURE 46 EUROPE BREAST CANCER DIAGNOSTICS MARKET: TEST TYPE (2023-2030)
FIGURE 47 ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022)
FIGURE 48 ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022)
FIGURE 49 ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030)
FIGURE 50 ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030)
FIGURE 51 ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET: TEST TYPE (2023-2030)
FIGURE 52 SOUTH AMERICA BREAST CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022)
FIGURE 53 SOUTH AMERICA BREAST CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022)
FIGURE 54 SOUTH AMERICA BREAST CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030)
FIGURE 55 SOUTH AMERICA BREAST CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030)
FIGURE 56 SOUTH AMERICA BREAST CANCER DIAGNOSTICS MARKET: TEST TYPE (2023-2030)
FIGURE 57 MIDDLE EAST AND AFRICA BREAST CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022)
FIGURE 58 MIDDLE EAST AND AFRICA BREAST CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022)
FIGURE 59 MIDDLE EAST AND AFRICA BREAST CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030)
FIGURE 60 MIDDLE EAST AND AFRICA BREAST CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030)
FIGURE 61 MIDDLE EAST AND AFRICA BREAST CANCER DIAGNOSTICS MARKET: TEST TYPE (2023-2030)
FIGURE 62 GLOBAL BREAST CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%)
FIGURE 63 NORTH AMERICA BREAST CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%)
FIGURE 64 EUROPE BREAST CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%)
FIGURE 65 ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%)
Méthodologie de recherche
La collecte de données et l'analyse de l'année de base sont effectuées à l'aide de modules de collecte de données avec des échantillons de grande taille. L'étape consiste à obtenir des informations sur le marché ou des données connexes via diverses sources et stratégies. Elle comprend l'examen et la planification à l'avance de toutes les données acquises dans le passé. Elle englobe également l'examen des incohérences d'informations observées dans différentes sources d'informations. Les données de marché sont analysées et estimées à l'aide de modèles statistiques et cohérents de marché. De plus, l'analyse des parts de marché et l'analyse des tendances clés sont les principaux facteurs de succès du rapport de marché. Pour en savoir plus, veuillez demander un appel d'analyste ou déposer votre demande.
La méthodologie de recherche clé utilisée par l'équipe de recherche DBMR est la triangulation des données qui implique l'exploration de données, l'analyse de l'impact des variables de données sur le marché et la validation primaire (expert du secteur). Les modèles de données incluent la grille de positionnement des fournisseurs, l'analyse de la chronologie du marché, l'aperçu et le guide du marché, la grille de positionnement des entreprises, l'analyse des brevets, l'analyse des prix, l'analyse des parts de marché des entreprises, les normes de mesure, l'analyse globale par rapport à l'analyse régionale et des parts des fournisseurs. Pour en savoir plus sur la méthodologie de recherche, envoyez une demande pour parler à nos experts du secteur.
Personnalisation disponible
Data Bridge Market Research est un leader de la recherche formative avancée. Nous sommes fiers de fournir à nos clients existants et nouveaux des données et des analyses qui correspondent à leurs objectifs. Le rapport peut être personnalisé pour inclure une analyse des tendances des prix des marques cibles, une compréhension du marché pour d'autres pays (demandez la liste des pays), des données sur les résultats des essais cliniques, une revue de la littérature, une analyse du marché des produits remis à neuf et de la base de produits. L'analyse du marché des concurrents cibles peut être analysée à partir d'une analyse basée sur la technologie jusqu'à des stratégies de portefeuille de marché. Nous pouvons ajouter autant de concurrents que vous le souhaitez, dans le format et le style de données que vous recherchez. Notre équipe d'analystes peut également vous fournir des données sous forme de fichiers Excel bruts, de tableaux croisés dynamiques (Fact book) ou peut vous aider à créer des présentations à partir des ensembles de données disponibles dans le rapport.
